Drugs / L19TNFa
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01253837 | Sep 2007 → May 2011 | colorectal cancer | Philogen S.p.A. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | L19TNFa | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01253837 ↗ |
| Known as | L19TNFα | “The recombinant human fusion protein L19TNFα was created with the intention to overcome the systemic toxicity of TNFα by directly targeting it to tumor tissues.” NCT01253837 ↗ |
| Modality | Monoclonal antibody | “Tumor-targeting Human L19TNFα Monoclonal Antibody-cytokine Fusion Protein” NCT01253837 ↗ |
| Target | FN1 | “Fibronectin binding agent” CHEMBL2109589 ↗ |